[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@JamesEKrause Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1091405261741404162.png) @JamesEKrause Biotech Jim

Biotech Jim posts on X about $crvs, $mdgl, $axsm, $idya the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1091405261741404162/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:interactions.svg)

- X Week XXXXXX -XX%
- X Month XXXXXX +96%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +57%

### Mentions: X [#](/creator/twitter::1091405261741404162/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:posts_active.svg)

- X Week XX +64%
- X Month XX +2.90%
- X Months XXX -XX%
- X Year XXX +177%

### Followers: XXXXXX [#](/creator/twitter::1091405261741404162/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:followers.svg)

- X Week XXXXXX +0.16%
- X Month XXXXXX +1.60%
- X Months XXXXXX +8.90%
- X Year XXXXXX +18%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1091405261741404162/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1091405261741404162/influence)
---

**Social category influence**
[finance](/list/finance)  XXXX% [stocks](/list/stocks)  XXXX%

**Social topic influence**
[$crvs](/topic/$crvs) #15, [$mdgl](/topic/$mdgl) 11.43%, [$axsm](/topic/$axsm) 5.71%, [$idya](/topic/$idya) 5.71%, [$mash](/topic/$mash) 2.86%, [targets](/topic/targets) 2.86%, [$imrx](/topic/$imrx) 2.86%, [$ocul](/topic/$ocul) 2.86%, [$23b](/topic/$23b) 2.86%, [new to](/topic/new-to) XXXX%

**Top accounts mentioned or mentioned by**
[@semodough](/creator/undefined) [@omillionaires](/creator/undefined) [@johnpdalyjr](/creator/undefined) [@tejada444](/creator/undefined) [@c16h14n2oaqua](/creator/undefined) [@playertwoq](/creator/undefined) [@seedy19tron](/creator/undefined) [@snupsnus](/creator/undefined) [@dudebiotech](/creator/undefined) [@wallstsai](/creator/undefined) [@cashinsider](/creator/undefined) [@badinvestor99](/creator/undefined) [@andre_agtc](/creator/undefined) [@mbbiotech](/creator/undefined) [@biopharmiq](/creator/undefined) [@jeremyfalmouth](/creator/undefined) [@bionavgator](/creator/undefined) [@wz2013](/creator/undefined) [@mufaso7](/creator/undefined) [@cann0l1](/creator/undefined)

**Top assets mentioned**
[Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Axsome Therapeutics, Inc (AXSM)](/topic/$axsm) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Novo-Nordisk (NVO)](/topic/$nvo) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Akropolis (AKRO)](/topic/$akro)
### Top Social Posts [#](/creator/twitter::1091405261741404162/posts)
---
Top posts by engagements in the last XX hours

"My comments for the circular file fwiw. $CRVS is my fav nascent up and coming biotech for several reasons. X. Innovation (early) on this target ITK inhibition with a compelling pleiotropic response X. Initial clinical target Peripheral T-cell Lymphoma (PTCL) with dramatic unmet medical need X. Large targeted inflammation markets with Atopic Dermatitis in the current cross hairs ( $REGN has a blockbuster here with the injectable mAb #dupixent targeting the IL-4R that then limits the production of both Il-4 and Il-13 pro-inflammatory cytokines X. Skilled CEO Richard Miller MD a #lymphoma doc"  
[X Link](https://x.com/JamesEKrause/status/1957093827875045565) [@JamesEKrause](/creator/x/JamesEKrause) 2025-08-17T14:55Z 13.2K followers, 10.8K engagements


"$CRVS is starting to get recognized"  
[X Link](https://x.com/JamesEKrause/status/1978536636733391182) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-15T19:01Z 13.2K followers, 10.1K engagements


"Madrigal's CEO Bill Seybold discusses the $MDGL $MASH market and sales on CNBC"  
[X Link](https://x.com/JamesEKrause/status/1978953279380787610) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-16T22:36Z 13.2K followers, 3865 engagements


"$AXSM Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025 Major Depressive Disorder Title: Initiating Auvelity (dextromethorphan XX mg-bupropion XXX mg) in Patients with Major Depressive Disorder: Expert Panel Consensus Recommendations Presentation Date and Time: Friday September XX 1:30 - 3:00 p.m. and 6:00 - 7:15 p.m.; Saturday September XX 1:30 - 3:00 p.m. PT Lead Author:Anita H. Clayton MD Professor and Chair of Psychiatry and Neurobehavioral Sciences at the University of Virginia School of Medicine Poster Number: XXX Alzheimers Disease"  
[X Link](https://x.com/JamesEKrause/status/1968283331381940576) [@JamesEKrause](/creator/x/JamesEKrause) 2025-09-17T11:58Z 13.2K followers, 2971 engagements


"A $CRVS ITK degrader program would definitely be of interest. I would assume significant ongoing competition"  
[X Link](https://x.com/JamesEKrause/status/1970833458353304044) [@JamesEKrause](/creator/x/JamesEKrause) 2025-09-24T12:51Z 13.2K followers, 4286 engagements


"$IMRX Company PR on pancreatic patient data update with Tebimetinib + MGNP note on stock offering and a Reuters News Brief. Sept XX (Reuters) 5:21 PM ET Immuneering Corp * IMMUNEERING ANNOUNCES EXTRAORDINARY XX% OVERALL SURVIVAL AT X MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP * IMMUNEERING CORP(IMRX) - ATEBIMETINIB + MGNP SHOWS XX% PFS AT X MONTHS IN PANCREATIC CANCER * IMMUNEERING CORP(IMRX) - EXPECTS REGULATORY FEEDBACK ON PIVOTAL TRIAL PLANS IN Q4 2025 * IMMUNEERING CORP(IMRX) - TO INITIATE PIVOTAL TRIAL BY END OF 2025"  
[X Link](https://x.com/JamesEKrause/status/1971000627325988965) [@JamesEKrause](/creator/x/JamesEKrause) 2025-09-24T23:55Z 13.2K followers, 6953 engagements


"@playerTwoQ @seedy19tron Taking profits from $MDGL And with some other multibagger biotechs bought in the april to june 2025 time frame"  
[X Link](https://x.com/JamesEKrause/status/1971545285429178601) [@JamesEKrause](/creator/x/JamesEKrause) 2025-09-26T12:00Z 13.2K followers, 1258 engagements


"@SnupSnus $MDGL $AXSM and $OCUL. But I must point out that $CRVS is rapidly approaching the 'Four Horsemen'. Please do and share your own due diligence"  
[X Link](https://x.com/JamesEKrause/status/1971613245883715667) [@JamesEKrause](/creator/x/JamesEKrause) 2025-09-26T16:30Z 13.2K followers, XXX engagements


"Performing some DD on $IDYA IDEAYA Biosciences trying to get a synopsis of their many biopharma collaborations. New to this name fwiw. Some friends of mine on X believe this company may be a buyout candidate. Current mkt cap $2.3B with some uncertainty of # of fully diluted shares (stock option grants etc). As usual please feel free to provide commentary (+ and -) on this interesting company/business plan. Partnered Programs and Collaborative Details via Grok my consultant. IDEAYA Biosciences has established multiple strategic partnerships to advance its precision oncology pipeline focusing"  
[X Link](https://x.com/JamesEKrause/status/1977085929811583266) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-11T18:56Z 13.2K followers, 16.7K engagements


"On the topic of 'why is Madrigal Pharmaceuticals $MDGL currently undervalued Current MDGL mkt cap $9.6B"  
[X Link](https://x.com/JamesEKrause/status/1977088199026786534) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-11T19:05Z 13.2K followers, 5906 engagements


"On the ITK enzyme and its inhibition for TH2 inflammatory diseases. I will be listening in on the Aclarus presentations today: Aclaris Therapeutics to Host In-Person and Webcast R&D Day Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets in New York on October XX 2025 $ACRS $CRVS"  
[X Link](https://x.com/JamesEKrause/status/1978082130614698409) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-14T12:55Z 13.2K followers, 8733 engagements


"Grok for the purposes of continuing due diligence tell me about the business plan pipeline most valuable asset the management and investors in Ideaya Biosciences $IDYA"  
[X Link](https://x.com/JamesEKrause/status/1979549315434770694) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-18T14:05Z 13.2K followers, 1863 engagements